Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446133 | 0.92 | LMNA (0.58) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL4918707 | 0.86 | LMNA (0.52) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL4920399 | 0.85 | LMNA (0.52) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL4916941 | 0.84 | LMNA (0.50) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL2997208 | 0.83 | LMNA (0.51) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL29445414 | 0.83 | LMNA (0.51) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL27707930 | 0.83 | LMNA (0.47) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL1085473 | 0.82 | LMNA (0.48) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL27737634 | 0.81 | LMNA (0.46) | CYP1A2CYP3A4CYP2C19CYP2C9LMNA | |
| SCHEMBL302846 | 0.81 | LMNA (0.61) | LMNAALDH1A1POLBSMN1; SMN2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042724-A1 | Fungicidal mixtures based on 2,4-disubstituted n-biphenylpyrazolecarboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2009-02-12 | — | — | US | claimed |
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | BASF AKITENGESELLSCHAFT (DE) | 2008-06-26 | — | — | US | claimed |
| US-20090042724-A1 | Fungicidal mixtures based on 2,4-disubstituted n-biphenylpyrazolecarboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | CBR3, C1S, PYM1 | CYP1A2 154/4885CYP3A4 97/4885CYP2C19 491/4885 |
| US-20090042724-A1 | Fungicidal mixtures based on 2,4-disubstituted n-biphenylpyrazolecarboxamides | CBR3, CBR1, SNU13 | CYP1A2 114/4885CYP3A4 181/4885CYP2C19 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.